Article Text

Download PDFPDF
Correspondence on ‘Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries’ by Sadek et al
  1. Erin Sadek1,
  2. Jason Hecht2
  1. 1Inpatient Pharmacy, Trinity Health - Ann Arbor, Ypsilanti, Michigan, USA
  2. 2Inpatient Pharmacy, Trinity Health Ann Arbor, Ann Arbor, Michigan, USA
  1. Correspondence to Dr Erin Sadek; erin.sadek{at}trinity-health.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We would like to thank the author for their comments. We would be happy to provide some further explanation regarding the questions and comments regarding our paper.1 A correction has now been issued for points (2) and (3).

(1) In regards to the cost discrepancy of andexanet alfa, we cited and referenced the correct cost of the medication as of 2019, at the time of the study. We do …

View Full Text

Footnotes

  • Handling editor Ellen J Weber

  • Contributors ES drafted the initial response, and ES and JH edited the response. ES is the guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles